Prognostic Value of Volume-Based Metabolic Parameters Measured by 18F-FDG PET/CT of Pancreatic Neuroendocrine Tumors

被引：31

作者：

Kim H.S. ^{[1
]}

Choi J.Y. ^{[1
]}

Choi D.W. ^{[2
]}

Lim H.Y. ^{[3
]}

Lee J.H. ^{[1
]}

Hong S.P. ^{[1
]}

Cho Y.S. ^{[1
]}

Lee K.-H. ^{[1
]}

Kim B.-T. ^{[1
]}

机构：

[1] Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 135-710, 50 Irwon-dong, Gangnam-gu

[2] Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 135-710, 50 Irwon-dong, Gangnam-gu

[3] Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 135-710, 50 Irwon-dong, Gangnam-gu

来源：

Nuclear Medicine and Molecular Imaging | 2014年 / 48卷 / 3期

关键词：

Metabolic tumor volume; Pancreatic neuroendocrine tumor; Prognosis; Total lesion glycolysis;

D O I：

10.1007/s13139-013-0262-0

中图分类号：

学科分类号：

摘要：

Purpose: To date, the prognostic value of 18F-FDG PET/CT for patients with pancreatic neuroendocrine tumors (PNETs) has not been well characterized. We investigated the prognostic value of volumetric parameters using 18F-FDG PET/CT in this patient population. Methods: We retrospectively reviewed 20 cases of pathologically proven PNET in patients who had undergone pre-therapeutic 18F-FDG PET/CT. PET parameters including maximum and average standardized uptake values (SUVmax, SUVave), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) of the primary tumor were measured using a threshold SUV to determine the boundaries of the tumors. Univariate and multivariate survival analyses were performed with adjustments for PET parameters and other clinical values. Results: The median clinical follow-up was 22.3 (range, 1.2-95.4) months. Cancer-related death occurred in 5 of 20 patients (25 %). Patients had clinical or pathological stages of I in seven patients, II in six patients, III in three patient, and IV in four patients. According to the WHO histological classification of subtypes, 3 patients exhibited well-differentiated PNETs, 13 patients had well-differentiated endocrine carcinomas, and 4 had poorly differentiatedendocrine carcinomas. Univariate analysis showed that tumor size (p = 0.028), AJCC stage (p = 0.009), T stage (p = 0.028), M stage (p = 0.029), treatment modality (p = 0.045), MTV (p = 0.003) and TLG (p = 0.027) were significant predictors of overall survival. On multivariate analysis, MTV (HR = 10.859, p = 0.031) was a significant independent predictor of overall survival along with the AJCC stage (HR = 11.556, p = 0.027). Conclusion: In patients with PNETs, the MTV of the primary tumor as measured by 18F-FDG PET/CT along with the AJCC stage may be a significant independent prognostic factor for overall survival. © 2014 Korean Society of Nuclear Medicine.

引用

页码：180 / 186

页数：6

共 30 条

[1]

Burns W.R., Edil B.H., Neuroendocrine pancreatic tumors: guidelines for management and update, Curr Treat Options Oncol, 13, pp. 24-34, (2012)

[2]

Modlin I.M., Lye K.D., Kidd M., A 5-decade analysis of 13,715 carcinoid tumors, Cancer, 97, pp. 934-959, (2003)

[3]

Han J.H., Kim M.H., Moon S.H., Park S.J., Park D.H., Lee S.S., Et al., Clinical characteristics and malignant predictive factors of pancreatic neuroendocrine tumors, Korean J Gastroenterol, 53, pp. 98-105, (2009)

[4]

Panzuto F., Nasoni S., Falconi M., Corleto V.D., Capurso G., Cassetta S., Et al., Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization, Endocr Relat Cancer, 12, pp. 1083-1092, (2005)

[5]

Delbeke D., Martin W.H., Positron emission tomography imaging in oncology, Radiol Clin N Am, 39, pp. 883-917, (2001)

[6]

Hustinx R., Benard F., Alavi A., Whole-body imaging in the management of patients with cancer, Sem Nucl Med, 32, pp. 35-46, (2002)

[7]

Toshihiko M., Ryuichiro D., Tatsuo I., Kazuhiro K., Kohei O., Daisuke H., Et al., Diagnostic value of 18F-fluorodeoxyglucose positron emission tomography for pancreatic neuroendocrine tumors with-reference to the World Health Organization classification, Oncol Lett, 1, pp. 155-159, (2010)

[8]

Yoo J., Choi J.Y., Lee K.T., Heo J.S., Park S.B., Moon S.H., Et al., Prognostic significance of volume-based metabolic parameters by 18F-FDG PET/CT in gallbladder carcinoma, Nucl Med Mol Imaging, 46, pp. 201-206, (2012)

[9]

Yoo J., Choi J.Y., Moon S.H., Bae D.S., Park S.B., Choe Y.S., Et al., Prognostic significance of volume-based metabolic parameters in uterine cervical cancer determined using 18F-FDG PET, Int J Gynecol Cancer, 22, pp. 1226-1233, (2012)

[10]

Moon S.H., Choi J.Y., Lee H.J., Son Y.I., Baek C.H., Ahn Y.C., Et al., Prognostic value of 18F-FDG PET/CT in patients with squamous cell carcinoma of the tonsil: comparisons of volume-based metabolic parameters, Head Neck, 35, pp. 15-22, (2013)

← 1 2 3 →